Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents
Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents
复制标题
DOI：
10.1038/eye.2016.208
复制
发表时间：
2017-01-01
期刊：
影响因子：
3.9
通讯作者：
Patel, P. J.
中科院分区：
文献类型：
--
作者：
Gemenetzi, M.;Lotery, A. J.;Patel, P. J.
抗血管内皮生长因子（VEGF）玻璃体内药物是湿性年龄相关性黄斑变性（AMD）的唯一成功治疗方法。然而，有新的信号表明，抗VEGF治疗可能会增加地图状萎缩（GA）的发展。组织病理学、动物和临床研究支持这一假设，尽管尚未建立GA与新生血管性AMD中抗VEGF药物使用之间关系的直接证据。本文综述了目前支持抗VEGF治疗与地图状萎缩进展相关的证据。间接但明确地强调了探索治疗AMD的替代方法的必要性。
Anti-vascular endothelial growth factor (VEGF) intravitreal agents are the only successful treatment for wet age-related macular degeneration (AMD). However, there are emerging signals that anti-VEGF treatment can potentially increase development of geographic atrophy (GA). Histopathologic, animal, and clinical studies support this hypothesis although direct proof of a relationship between GA and use of anti-VEGF agents in neovascular AMD is not yet established. This review presents current evidence supporting an association between anti-VEGF therapy and progression of geographic atrophy. The need of exploring alternative methods of treating AMD is indirectly but clearly emphasized.